Skip to main content

Advertisement

SpringerLink
Log in

Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

In most patients, mantle cell lymphoma (MCL) shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3–5 years. In the current study generation of the European MCL Network, the addition of high-dose Ara-C to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen followed by myeloablative consolidation achieved a significant improvement of progression-free survival in younger patients. In elderly patients, rituximab maintenance led to a marked prolongation of remission duration. Emerging strategies include mammalian target of rapamycin (mTOR) inhibitors, proteasome inhibitors, immune modulatory drugs, Bruton’s tyrosine kinase inhibitors and others, all based on the dysregulated control of cell cycle machinery and impairment of several apoptotic pathways. Combination strategies are currently being investigated in numerous trials, but their introduction into clinical practice and current treatment algorithms remains a challenge. In the current survey, the application of the molecular targeted compounds were collected and evaluated by a representative national network of 14 haematological institutions. Optimised strategies are recommended for clinical routine. Future studies will apply individualised approaches according to the molecular risk profile of the patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, France

    Google Scholar 

  2. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27(4):511–518

    Article  PubMed  Google Scholar 

  3. Dreyling M, Hiddemann W (2009) Current treatment standards and emerging strategies in mantle cell lymphoma. Am Soc Hematol Educ Program Book Hematol 542–554

  4. Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Trümper L, Hallek M, Wörmann B, Dührsen U, Gisselbrecht C, Kluin-Nelemans H, van Hoof A, Unterhalt M, Hiddemann W, Dreyling M (2009) Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood 114(suppl 1):#880

    Google Scholar 

  5. Kluin-Nelemans JC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler C, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduikn J, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu S, Sanhes L, Zijlstra J, Bouabdallah R, Lugtenburg P, Macro M, Pfreundschuh M, Prochazka V, Di Raimondo F, Ribrag V, Uppenkamp M, Andre A, Klapper W, Hiddemann W, Unterhalt M, Dreyling M (2012) Therapy in older patients with mantle cell lymphoma. New Engl J Med 2012 (in press).

  6. Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron J, Boogaerts M, Aldaoud A, Silingardi V, Kluin-Nelemans H, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105(7):2677–2684

    Article  PubMed  CAS  Google Scholar 

  7. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9):1984–1992

    Article  PubMed  CAS  Google Scholar 

  8. Hoster E, Unterhalt M, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H. Steinhauer H, Martin S, Heidemann E, Aldaoud A, Hiddemann W, Dreyling M (2008) The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. Blood 112(suppl 1):#3049

    Google Scholar 

  9. Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C, Bouabdallah R, Stilgenbauer S, Feugier P, Forstpointner R, Haioun C, Kneba M, Hänel M, - Casasnovas R, Finke J, Hallek M, Wandt H, Bosly A, Klapper W, Gisselbrecht C, Coiffier B, Hiddemann W, Unterhalt M, Dreyling M (2010) “Alternating courses of 3× CHOP and 3× DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net).” Blood 116(Suppl. 1):#110

  10. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687–2693

    Article  PubMed  CAS  Google Scholar 

  11. Unterhalt M, Hermann R, Koch P, Trümper L, Bodenstein H, Dietzfelbinger H, Landys K, Reuß M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, Hiddemann W (1996) Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 88(suppl 1):453a

    Google Scholar 

  12. Rummel M (2009) “Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)” Blood 114(No 21): #405.

  13. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822–3829

    Article  PubMed  CAS  Google Scholar 

  14. Zoellner A, Bayerl S, Weinkauf M, Hiddemann W, Dreyling M (2011) Temsirolimus and chemotherapy show additive effects and target independent cell programs (cell cycle, apoptosis) in diffuse large cell B cell lymphoma. Onkologie Band 34(suppl 6):#P271

    Google Scholar 

  15. Hess G, Keller U, Atta J, Buske C, Borchmann P, Medler C, Witzens-Harig M, Dreyling M (2011) Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I/II trial. Blood 118(suppl 1):#2697

  16. Ansell S, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, Erlichman C, Witzig TE (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12(4):361–368

    Article  PubMed  CAS  Google Scholar 

  17. Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell 79(1):13–21

    Article  PubMed  CAS  Google Scholar 

  18. Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14(6):1649–1657

    Article  PubMed  CAS  Google Scholar 

  19. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O’Connor OA, Shi H, Boral AL, Goy A (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24(30):4867–4874

    Article  PubMed  Google Scholar 

  20. O’Connor O, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, Gonen M, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J (2009) Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. Br J Haematol 145(1):34–39

    Article  PubMed  Google Scholar 

  21. Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, Zhang Z, Dumitrescu O, Sarasohn D, Lin D, Pappanicholaou J, Cortelli BM, Neylon E, Hamelers R, Wright J, O’Connor OA (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 146(6):652–655

    Article  PubMed  CAS  Google Scholar 

  22. Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J (2011) Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 96(7):1008–1014

    Article  PubMed  Google Scholar 

  23. Friedberg J, Vose J, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117(10):2807–2812

    Article  PubMed  CAS  Google Scholar 

  24. Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R, Jentsch-Ullrich K, Hiddemann W, Dreyling M (2009) A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma—long-term results of a multicenter observation study. Leuk Lymphoma 50(5):716–722

    Article  PubMed  CAS  Google Scholar 

  25. Wiernik P, Lossos I, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 26(30):4952–4957

    Article  PubMed  Google Scholar 

  26. Habermann T, Lossos I, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145(3):344–349

    Article  PubMed  CAS  Google Scholar 

  27. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 22(7):1622–1627

    Article  PubMed  CAS  Google Scholar 

  28. Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, Rusconi C, Ravelli E, Tucci A, Bottelli C, Balzarotti M, Brusamolino E, Bonfichi M, Pileri SA, Sabattini E, Volpetti S, Monagheddu C, Vacca A, Ria R, Fanin R (2012) Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 97(3):416–422

    Article  PubMed  Google Scholar 

  29. Hutchins LF, Unger JM et al (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–2067

    Article  PubMed  CAS  Google Scholar 

  30. Wang L, Martin P, Blum KA, Kahl BS, Maeda LS, Advani R, Williams ME, Rule S, Rodriguez S, Pang CF, Hedrick E, Goy A (2011) The Bruton’s tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Blood 118(suppl 1):#442

    Google Scholar 

  31. Herold M, Haas A, Doerken B, Neser S, Al Ali K, Neubauer A, Dölken G (2008) R-MCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone - 50 months up date of the OSHO phase III study. Ann Oncol 19(suppl 4):iv85, #012

    Google Scholar 

  32. Romaguera J, Fayad L, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A (2010) Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200–208

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Heidelberg Hospital, Heidelberg, Germany

    M. Witzens-Harig

  2. University of Mainz Hospital, Mainz, Germany

    G. Hess

  3. University of Frankfurt Hospital, Frankfurt, Germany

    J. Atta

  4. Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg, Germany

    M. Zaiss

  5. Department of Hematology, Oncology and Tumorimmunology, Charite-Universitätsmedizin-Berlin, Berlin, Germany

    G. Lenz & C. Scholz

  6. Klinikum am Bruderwald, Bamberg, Germany

    R. Repp

  7. Praxis internistische Onkologie und Hämatologie, Cologne, Germany

    M. Reiser

  8. University of Schleswig-Holstein Hospital, Campus Kiel, Kiel, Germany

    C. Pott

  9. Schwerpunktpraxis Hämatologie und Onkologie, Münster, Germany

    H. Pelz

  10. University of Jena Hospital, Jena, Germany

    P. La Rosée

  11. Krankenhaus Siloah, Hannover, Germany

    H. Kirchner

  12. Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany

    P. Kiewe

  13. University of Munich Hospital, Campus Rechts der Isar, Munich, Germany

    U. Keller

  14. Comprehensive Cancer Centre Ulm, Institute of Experimental Cancer Research, Ulm, Germany

    C. Buske

  15. Department of Internal Medicine 3, University Hospital of Ulm, Ulm, Germany

    A. Viardot

  16. University of Munich Hospital, Campus Großhadern, Munich, Germany

    M. Dreyling

Authors
  1. M. Witzens-Harig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Hess
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Atta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Zaiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Lenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Scholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Repp
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Reiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Pott
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H. Pelz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P. La Rosée
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H. Kirchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P. Kiewe
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. U. Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. C. Buske
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A. Viardot
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M. Dreyling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Dreyling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Witzens-Harig, M., Hess, G., Atta, J. et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol 91, 1765–1772 (2012). https://doi.org/10.1007/s00277-012-1534-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1534-y

Keywords

Search

Navigation